Genetic modifiers of sickle cell disease

American Journal of Hematology

Volumn 87, Issue 8, 2012, Pages 795-803

  Steinberg, Martin H ^a   Sebastiani, Paola ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN F;

ALPHA THALASSEMIA; DNA MODIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SICKLE CELL ANEMIA;

ALPHA-THALASSEMIA; ANEMIA, SICKLE CELL; FEMALE; FETAL HEMOGLOBIN; GENOME, HUMAN; HUMANS; MALE;

EID: 84864016792     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23232     Document Type: Review

References (159)

1. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Disorders of Hemoglobin: Genetics Pathophysiology Clinical Management, 2nd ed. Cambridge: Cambridge University Press; 2009.
2. Serjeant GR, Richards R, Barbor PR, Milner PF. Relatively benign sickle-cell anaemia in 60 patients aged over 30 in the West Indies. Br Med J 1968; 3: 86-91.
3. Steinberg MH, Dreiling BJ, Morrison FS, Necheles TF. Mild sickle cell disease. Clinical and laboratory studies. JAMA 1973; 224: 317-321.
4. Steinberg MH, Embury SH. Alpha-thalassemia in blacks: Genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood 1986; 68: 985-990.
5. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol 2005; 129: 465-481.
6. Thein SL. Genetic modifiers of the beta-haemoglobinopathies. Br J Haematol 2008; 141: 357-366.
7. Driss A, Asare KO, Hibbert JM, et al. Sickle cell disease in the post genomic era: A monogenic disease with a polygenic phenotype. Genomics Insights 2009; 2009: 23-48.
8. Steinberg MH. Genetic etiologies for phenotypic diversity in sickle cell anemia. ScientificWorldJournal 2009; 9: 46-67.
9. Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009; 145: 455-467.
10. Fertrin KY, Costa FF. Genomic polymorphisms in sickle cell disease: Implications for clinical diversity and treatment. Expert Rev Hematol 2010; 3: 443-458.
11. Thein SL. Genetic modifiers of sickle cell disease. Hemoglobin 2011; 35: 589-606.
12. Poillon WN, Kim BC, Rodgers GP, et al. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci USA 1993; 90: 5039-5043.
13. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011; 118: 19-27.
14. Wilber A NA, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: New therapeutic opportunities. Blood 2011; 117: 3945-3953.
15. Murray N, Serjeant BE, Serjeant GR. Sickle cell-hereditary persistence of fetal haemoglobin and its differentiation from other sickle cell syndromes. Br J Haematol 1988; 69: 89-92.
16. Ngo DA, Akinsheye I, Hankins JS, et al. Fetal hemoglobin levels and hematologic characteristics of compound heterozygotes for HbS and deletional hereditary persistence of fetal hemoglobin. Br J Haematol 2011;156:259-264.
17. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21: 37-47.
18. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651.
19. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
20. Serjeant GR, Serjeant BE, Mason KP, et al. The changing face of homozygous sickle cell disease:102 patients over 60 years. Int J Lab Hematol 2008; 31: 585-596.
21. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle-cell syndromes: Results of a 17-year, single center trial (LaSHS). Blood 2010; 115: 2554-2563.
22. Bakanay SM, Dainer E, Clair B, et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood 2004; 105: 545-547.
23. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease-rates and risk factors. N Engl J Med 1991; 325: 11-16.
24. Bailey K, Morris JS, Thomas P, Serjeant GR. Fetal haemoglobin and early manifestations of homozygous sickle cell disease. Arch Dis Child 1992; 67: 517-520.
25. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: Incidence and risk factors. Blood 1994; 84: 643-649.
26. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: Associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006; 133: 570-578.
27. Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood 1989; 74: 1403-1408.
28. Cumming V, King L, Fraser R, et al. Venous incompetence, poverty and lactate dehydrogenase in Jamaica are important predictors of leg ulceration in sickle cell anaemia. Br J Haematol 2008; 142: 119-125.
29. Adekile AD. Limitations of Hb F as a Phenotypic modifiers in sickle cell disease: Study of Kuwaiti Arab patients. Hemoglobin 2011; 35: 607-617.
30. Baldwin C, Nolan VG, Wyszynski DF, et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood 2005; 106: 372-375.
31. Hawker H, Neilson H, Hayes RJ, Serjeant GR. Haematological factors associated with avascular necrosis of the femoral head in homozygous sickle cell disease. Br J Haematol 1982; 50: 29-34.
32. Mahadeo KM, Oyeku S, Taragin B, et al. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease. Am J Hematol 2011; 86: 806-808.
33. Diop S, Diop D, Seck M, et al. Predictive factors of chronic complications in adult sickle cell anemia patients in Dakar, Senegal. Medecine Tropicale: Revue du Corps de Sante Colonial 2010; 70: 471-474.
34. Mukisi-Mukaza M, Elbaz A, Samuel-Leborgne Y, et al. Prevalence, clinical features, and risk factors of osteonecrosis of the femoral head among adults with sickle cell disease. Orthopedics 2000; 23: 357-363.
35. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood 2005; 106: 3264-3267.
36. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 1980; 140: 1434-1437.
37. Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell anemia: Baseline data from the BABY HUG trial. J Pediatr 2010; 156: 66-70 e1.
38. Powars DR, Elliott Mills DD, Chan L. Chronic renal failure in sickle cell disease: Risk factors, clinical course, and mortality. Ann Intern Med 1991; 115: 614-620.
39. Wigfall DR, Ware RE, Burchinal MR, et al. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr 2000; 136: 749-753.
40. Becton LJ, Kalpatthi RV, Rackoff E, et al. Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease. Pediatr Nephrol 2010; 25: 1505-1511.
41. King L, Moosang M, Miller M, Reid M. Prevalence and predictors of microalbuminuria in Jamaican children with sickle cell disease. Arch Dis Childhood 2011; 96: 1135-1139.
42. Haymann JP, Stankovic K, Levy P, et al. Glomerular hyperfiltration in adult sickle cell anemia: A frequent hemolysis associated feature. Clin J Am Soc Nephrol 2010; 5: 756-761.
43. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: A risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 1999; 103: 640-645.
44. Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol 2009; 146: 300-305.
45. Ohene-Frempong K. Stroke in sickle cell disease: Demographic, clinical, and therapeutic considerations. Semin Hematol 1991; 28: 213-219.
46. Hsu LL, Miller ST, Wright E, et al. Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia. J Pediatr Hematol Oncol 2003; 25: 622-628.
47. Wang WC, Pavlakis SG, Helton KJ, et al. MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatric Blood & Cancer 2008; 51: 643-646.
48. Rogers ZR, Wang WC, Luo Z, et al. Biomarkers of splenic function in infants with sickle cell anemia: Baseline data from the BABY HUG Trial. Blood 2011; 117: 2614-2617.
49. Adewoye AH, Nolan VG, Ma Q, et al. Association of polymorphisms of IGF1R and genes in the transforming growth factor- beta/bone morphogenetic protein pathway with bacteremia in sickle cell anemia. Clin Infect Dis 2006; 43: 593-598.
50. Webb DK, Darby JS, Dunn DT, et al. Gall stones in Jamaican children with homozygous sickle cell disease. Arch Dis Childhood 1989; 64: 693-696.
51. Talbot JF, Bird AC, Rabb LM, et al. Sickle cell retinopathy in Jamaican children: A search for prognostic factors. Br J Ophthalmol 1983; 67: 782-785.
52. Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients with sickle cell disease: A longitudinal study. Br J Haematol 2006; 134: 109-115.
53. Gordeuk VR, Campbell A, Rana S, et al. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood 2009; 114: 4639-4644.
54. Voskaridou E, Tsetsos G, Tsoutsias A, et al. Pulmonary hypertension in patients with sickle cell/beta thalassemia: Incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica 2007; 92: 738-743.
55. Sachdev V, Kato GJ, Gibbs JS, et al. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation 2011; 124: 1452-1460.
56. Morris JS, Dunn DT, Poddar D, Serjeant GR. Haematological risk factors for pregnancy outcome in Jamaican women with homozygous sickle cell disease. Br J Obstet Gynaecol 1994; 101: 770-773.
57. Franco RS, Yasin Z, Palascak MB, et al. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 2006; 108: 1073-1076.
58. Serjeant G, Serjeant B, Stephens A, et al. Determinants of haemoglobin level in steady-state homozygous sickle cell disease. Br J Haematol 1996; 92: 143-149.
59. Donaldson A, Thomas P, Serjeant BE, Serjeant GR. Foetal haemoglobin in homozygous sickle cell disease: A study of patients with low HbF levels. Clin Lab Haematol 2001; 23: 285-289.
60. Powars DR, Schroeder WA, Weiss JN, et al. Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia. J Clin Invest 1980; 65: 732-740.
61. Powars DR, Meiselman HJ, Fisher TC, et al. Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia. Use in predicting clinical severity. Am J Pediatr Hematol Oncol 1994; 16: 55-61.
62. Garner C, Tatu T, Reittie JE, et al. Genetic influences on F cells and other hematologic variables: A twin heritability study. Blood 2000; 95: 342-346.
63. Dover GJ, Boyer SH, Pembrey ME. F-cell production in sickle cell anemia: Regulation by genes linked to beta-hemoglobin locus. Science 1981; 211: 1441-1444.
64. Gibney GT, Panhuysen CI, So JC, et al. Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong Kong. Am J Hematol 2008; 83: 458-464.
65. Steinberg MH, Nagel RL. Hemoglobins of the embryo, fetus, and adult. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, editors. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 2nd ed.Cambridge: Cambridge University Press; 2009. pp 119-135.
66. Stamatoyannopoulos G, Papayannopoulou T. The switching from hemoglobin F to hemoglobin A formation in man: Parallels between the observations n vivo and the findings in erythroid cultures. Prog Clin Bioll Res 1981; 55: 665-678.
67. Nagel RL, Steinberg MH. Genetics of the βS gene: Origins, epidemiology, and epistasis. In: Steinberg MH, Forget BG, Higgs DR, Nagel X RL, editors. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 1st ed. Cambridge: Cambridge University Press; 2001. pp 711-755.
68. Miller BA, Salameh M, Ahmed M, et al. Analysis of hemoglobin F production in Saudi Arabian families with sickle cell anemia. Blood 1987; 70: 716-720.
69. Padmos MA, Roberts GT, Sackey K, et al. Two different forms of homozygous sickle cell disease occur in Saudi Arabia. Br J Haematol 1991; 79: 93-98.
70. Adekile A, Al-Kandari M, Haider M, Rajaa M, D'Souza M, Sukumaran J. Hemoglobin F concentration as a function of age in Kuwaiti sickle cell disease patients. Med Princ Pract 2007; 16: 286-290.
71. Lapoumeroulie C, Dunda O, Ducrocq R, et al. A novel sickle cell mutation of yet another origin in Africa: The Cameroon type. Hum Genet 1992; 89: 333-337.
72. Nagel RL. Origins and dispersion of the sickle gene. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, editors. Sickle Cell Disease: Basic Principles and Clincal Practice. New York: Raven Press; 1994. pp 353-380.
73. Miller BA, Salameh M, Ahmed M, et al. Analysis of high fetal hemoglobin production in sickle cell anemia patients from the Eastern Province of Saudi Arabia. Prog Clin Biol Res 1987; 251: 415-426.
74. Labie D, Pagnier J, Lapoumeroulie C, et al. Common haplotype dependency of high Gγ-globin gene expression and high HbF levels in β_thalassemia andsickle cell anemia patients. Proc Natl Acad Sci USA 1985; 82: 2111-2114.
75. Nagel RL, Fabry ME, Pagnier J, et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type. N Engl J Med 1985; 312: 880-884.
76. Akinsheye I, Solovieff N, Ngo D, et al. Fetal hemoglobin in sickle cell anemia: Molecular characterization of the unusually high fetal hemoglobin phenotype in African Americans. Am J Hematol 2012; 87: 217-219.
77. Alsultan A, Solovieff N, Aleem A, et al. Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans. Am J Hematol 2011; 86: 612-614.
78. Alsultan A, Aleem A, Ghabbour H, et al. Sickle cell disease subphenotypes in patients from Southwestern Province of Saudi Arabia. J Pediatr Hematol Oncol 2012.
79. Kulozik AE, Yarwood N, Jones RW. The Corfu delta beta zero thalassemia: A small deletion acts at a distance to selectively abolish beta globin gene expression. Blood 1988; 71: 457-462.
80. Sankaran VG, Xu J, Byron R, et al. A functional element necessary for fetal hemoglobin silencing. N Engl J Med 2011; 365: 807-814.
81. Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: Genome-wide association studies suggest a regulatory region in the 5′ olfactory receptor gene cluster. Blood 2010; 115: 1815-1822.
82. Feingold EA, Penny LA, Nienhuis AW, Forget BG. An olfactory receptor gene is located in the extended human β-globin gene cluster and is expressed in erythroid cells. Genomics 1999; 61: 15-23.
83. Galarneau G, Palmer CD, Sankaran VG, et al. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet 2010; 42: 1049-1051.
84. Jiang J, Best S, Menzel S, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 2006; 108: 1077-1083.
85. Sankaran VG, Menne TF, Scepanovic D, et al. MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA 2011; 108: 1519-1524.
86. Badens C, Joly P, Agouti I, et al. Variants in genetic modifiers of beta-thalassemia can help to predict the major or intermedia type of the disease. Haematologica 2011; 96: 1712-1714.
87. Farrell JJ, Sherva RM, Chen ZY, et al. A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. Blood 2011; 117: 4935-4945.
88. Makani J, Menzel S, Nkya S, et al. Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood 2011; 117: 1390-1392.
89. Menzel S, Qin J, Vasavda N, et al. Experimental generation of SNP haplotype signatures in patients with sickle cell anaemia. PLoS One 2010; 5: e13004.
90. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 2008; 105: 11869-11874.
91. Creary LE, Ulug P, Menzel S, et al. Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients. PLoS One 2009; 4: e4218.
92. Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci USA 2007; 104: 11346-11351.
93. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 2007; 39: 1197-1199.
94. Bhatnagar P, Purvis S, Barron-Casella E, et al. Genome-wide association study identifies genetic variants influencing F-cell levels in sickle-cell patients. J Hum Genet 2011; 56: 316-323.
95. Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 1997; 89: 1078-1088.
96. Sedgewick A, Timofeev N, Sebastiani P, et al. BCL11A (2p16) is a major HbF quantitative trait locus in three different populations. Blood Cells Mol Dis 2008; 41: 255-258.
97. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA 2008; 105: 1620-1625.
98. Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: New insights emerging from genomics and clinical implications. Hum Mol Genet 2009; 18. pp R216-R223.
99. Siatecka M, Bieker JJ. The multifunctional role of EKLF/KLF1 during erythropoiesis. Blood 2011; 118: 2044-2054.
100. Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010; 42: 801-805.
101. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1317-1322.
102. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85: 403-408.
103. Steinberg MH, Voskaridou E, Kutlar A, et al. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol 2003; 72: 121-126.
104. Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: Genetic determinants of response to hydroxyurea. Pharmacogenomics J 2007; 7: 386-394.
105. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004; 364: 1343-1360.
106. Flanagan JM, Frohlich DM, Howard TA, et al. Genetic predictors for stroke in children with sickle cell anemia. Blood 2011; 117: 6681-6684.
107. Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37: 435-440.
108. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995; 86: 776-783.
109. Belisario AR, Rodrigues CV, Martins ML, et al. Coinheritance of alpha-thalassemia decreases the risk of cerebrovascular disease in a cohort of children with sickle cell anemia. Hemoglobin 2010; 34: 516-529.
110. Bernaudin F, Verlhac S, Chevret S, et al. G6PD deficiency, absence of alpha-thalassemia and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood 2008; 112: 4314-4317.
111. Darbari DS, Onyekwere O, Nouraie M, et al. Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr 2012; 160: 286-290.
112. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991; 325: 1476-1481.
113. Taylor JG, Ackah D, Cobb C, et al. Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol 2008; 83: 6-14.
114. De Ceulaer K, Serjeant GR. Acute splenic sequestration in Jamaican adults with homozygous sickle cell disease: A role of alpha thalassaemia. Br J Haematol 1991; 77: 563-564.
115. Wali YA, Al Lamki Z, Hussein SS, et al. Splenic function in Omani children with sickle cell disease: Correlation with severity index, hemoglobin phenotype, iron status, and alpha-thalassemia trait. Pediatr Hemato Oncol 2002; 19: 491-500.
116. Vasavda N, Menzel S, Kondaveeti S, et al. The linear effects of alpha-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease. Br J Haematol 2007; 138: 263-270.
117. Guasch A, Zayas CF, Eckman JR, Muralidharan K, Zhang W, Elsas LJ. Evidence that microdeletions in the à globin gene protect against the development of sickle cell glomerulopathy in humans. J Am Soc Nephrol 1999; 10: 1014-1019.
118. Nebor D, Broquere C, Brudey K, et al. Alpha-thalassemia is associated with a decreased occurrence and a delayed age-at-onset of albuminuria in sickle cell anemia patients. Blood Cells Mol Dis 2010; 45: 154-158.
119. Day TG, Drasar ER, Fulford T, et al. Association between hemolysis and albuminuria in adults with sickle cell anemia. Haematologica 2012; 97: 201-205
120. Condon PI, Marsh RJ, Maude GH, et al. Alpha thalassaemia and the macular vasculature in homozygous sickle cell disease. Br J Ophthalmol 1983; 67: 779-781.
121. Taylor JG, Nolan VG, Mendelsohn L, et al. Chronic hyper-hemolysis in sickle cell anemia: Association of vascular complications and mortality with infrequent vasoocclusive pain. PLoS One 2008; 3: e2095.
122. Driscoll MC, Hurlet A, Styles L, et al. Stroke risk in siblings with sickle cell anemia. Blood 2003; 101: 2401-2404.
123. Martinez-Castaldi C, Nolan VG, Baldwin CT, et al. Association of genetic polymorphisms in the TGF-β pathway with the acute chest syndrome of sickle cell disease. Blood 2007; 110: 2247a.
124. Taylor JG, Belfer I, Desai K, et al. A GCH1 haplotype associated with susceptibility to vasoocclusive pain and impaired vascular function in sickle cell anemia. Blood 2009; 114: 575a.
125. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007; 8: 253-262.
126. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-1068.
127. Sebastiani P, Wang L, Perls T, et al. A repertoire of genes modifying the risk of death in sickle cell anemia. Blood 2007; 110: 52a.
128. Taylor JG, Tang DC, Savage SA, et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 2002; 100: 4303-4309.
129. Hoppe C, Klitz W, Cheng S, et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood 2004; 103: 2391-2396.
130. Mendonca TF, Oliveira MC, Vasconcelos LR, et al. Association of variant alleles of MBL2 gene with vasoocclusive crisis in children with sickle cell anemia. Blood Cells Mol Dis 2010; 44: 224-228.
131. Oliveira MC, Mendonca TF, Vasconcelos LR, et al. Association of the MBL2 gene EXON1 polymorphism and vasoocclusive crisis in patients with sickle cell anemia. Acta Haematol 2009; 121: 212-215.
132. Al-Subaie AM, Fawaz NA, Mahdi N, et al. Human platelet alloantigens (HPA) 1, HPA2, HPA3, HPA4, and HPA5 polymorphisms in sickle cell anemia patients with vaso-occlusive crisis. Eur J Haematol 2009; 83: 579-585.
133. Sharan K, Surrey S, Ballas S, et al. Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br J Haematol 2004; 124: 240-243.
134. Sullivan KJ, Kissoon N, Duckworth LJ, et al. Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Respir Crit Care Med 2001; 164: 2186-2190.
135. Neonato MG, Lu CY, Guilloud-Bataille M, et al. Genetic polymorphism of the mannose-binding protein gene in children with sickle cell disease: Identification of three new variant alleles and relationship to infections. Eur J Hum Genet 1999; 7: 679-686.
136. Dossou-Yovo OP, Zaccaria I, Benkerrou M, et al. Effects of RANTES and MBL2 gene polymorphisms in sickle cell disease clinical outcomes: Association of the g.In1.1T>C RANTES variant with protection against infections. Am J Hematol 2009; 84: 378-380.
137. Zimmerman SA, Ware RE. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol 1998; 59: 267-272.
138. Ulug P, Vasavda N, Awogbade M, et al. Association of sickle avascular necrosis with bone morphogenic protein 6. Ann Hematol 2009; 88: 803-805.
139. Castro V, Alberto FL, Costa RN, et al. Polymorphism of the human platelet antigen-5 system is a risk factor for occlusive vascular complications in patients with sickle cell anemia. Vox Sanguinis 2004; 87: 118-123.
140. Nolan VG, Baldwin CT, Ma QL, et al. Association of single nucleotide polymorphisms in KLOTHO with priapism in sickle cell anemia. Br J Haematol 2004; 128: 266-272.
141. Elliott L, Ashley-Koch AE, De CL, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol 2007; 137: 262-267.
142. Lustosa Souza CR, Azavedo Shinmoto MM, Vicari P, et al. Klotho polymorphisms and priapism in sickle cell disease. Blood 2010; 116: 1653a.
143. Ofosu MD, Castro O, Alarif L. Sickle cell leg ulcers are associated with HLA-B35 and Cw4. Arch Dermatol 1987; 123: 482-484.
144. Ashley-Koch AE, Elliott L, Kail ME, et al. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 2008; 111: 5721-5726.
145. Passon RG, Howard TA, Zimmerman SA, et al. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol 2001; 23: 448-451.
146. Fertrin KY, Melo MB, Assis AM, et al. UDP-glucuronosyltransferase 1 gene promoter polymorphism is associated with increased serum bilirubin levels and cholecystectomy in patients with sickle cell anemia. Clin Genet 2003; 64: 160-162.
147. Nolan VG, Ma Q, Cohen HT, et al. Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B. Am J Hematol 2007; 82: 179-184.
148. Ashley-Koch AE, Okocha EC, Garrett ME, et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011; 155: 386-394.
149. Afenyi-Annan A, Kail M, Combs MR, et al. Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion 2008; 48: 917-924.
150. Nebor D, Durpes MC, Mougenel D, et al. Association between Duffy antigen receptor for chemokines expression and levels of inflammation markers in sickle cell anemia patients. Clin Immunol 2010; 136: 116-122.
151. Joly P, Gagnieu MC, Bardel C, et al. Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. 2012. Am J Hematol. DOI: 10.1002/ajh.23137.
152. Sebastiani P, Timofeev N, Dworkis DA, et al. Genome-wide association studies and the genetic dissection of complex traits. Am J Hematol 2009; 84: 504-515.
153. Milton JN, Sebastiani P, Solovieff N, et al. A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia. Plos One 2012, in press
154. Milton JN, et al. Clinical and genetic variability of red blood cell hemolysis in sickle cell disease. Blood 2011; 118:1077a.
155. Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: Association with hemolysis and hemoglobin oxygen desaturation. Haematologica 2009; 94: 340-347.
156. Hughes JR, Cheng JF, Ventress N, et al. Annotation of cis-regulatory elements by identification, subclassification, and functional assessment of multispecies conserved sequences. Proc Natl Acad Sci USA 2005; 102: 9830-9835.
157. Sebastiani P, Nolan VG, Baldwin CT, et al. A network model to predict the risk of death in sickle cell disease. Blood 2007; 110: 2727-2735.
158. Sebastiani P, Solovieff N, Hartley SW, et al. Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol 2010; 85: 29-35.
159. Herskind AM, McGue M, Holm NV, et al. The heritability of human longevity: A population-based study of 2872 Danish twin pairs born 1870-1900. Hum Genet 1996; 97: 319-323.